<DOC>
	<DOCNO>NCT00005576</DOCNO>
	<brief_summary>Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Colony-stimulating factor sargramostim may increase number immune cell find bone marrow peripheral blood . Interleukin-2 may stimulate person 's white blood cell kill cancer cell . Combining monoclonal antibody therapy sargramostim interleukin-2 may kill tumor cell . Phase I trial study effectiveness monoclonal antibody therapy give sargramostim interleukin-2 treat child neuroblastoma complete bone marrow peripheral stem cell transplantation</brief_summary>
	<brief_title>Monoclonal Antibody Therapy With Sargramostim Interleukin-2 Treating Children With Neuroblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose monoclonal antibody ( MOAB ) ch14.18 combine sargramostim ( GM-CSF ) interleukin-2 ( IL-2 ) autologous bone marrow peripheral blood stem cell rescue child neuroblastoma . II . Determine toxic effect regimen patient . III . Determine pharmacokinetics , include antibody level , antibody-binding activity , presence human anti-chimeric antibody , regimen patient . IV . Determine activity IL-2 MOAB ch14.18 tumor cell term response use standard clinical measurement bone marrow immunocytology patient . V. Determine extent coat tumor cell ( bone marrow metastasis ) MOAB ch14.18 patient . VI . Determine feasibility isotretinoin administer course begin course 2 patient . OUTLINE : This multicenter , dose-escalation study monoclonal antibody ( MOAB ) . Patients receive MOAB IV 5 hour day 7-10 course 2 4 day 3-6 course 1 , 3 , 5 ; sargramostim ( GM-CSF ) IV 2 hour subcutaneously daily day 0-13 course 1 , 3 , 5 ; interleukin-2 IV continuously day 0-3 7-10 course 2 4 ; oral isotretinoin twice daily day 14-27 course 2 4 day 10-23 course 3 5 . Treatment repeat every 24-32 day 5 course absence unacceptable toxicity . Cohorts 3-6 patient receive escalate dos MOAB maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . A minimum 6 additional patient treat MTD . Patients follow every week 2 month every 3 month 6 month . PROJECTED ACCRUAL : Approximately 6-16 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>Must recently complete course myeloablative therapy follow autologous stem cell ( bone marrow peripheral blood ) rescue ( ASCT ) Patients must diagnosis neuroblastoma base upon tumor histology bone marrow metastasis elevate urine catecholamine metabolite ; great 98 % neuroblastomas GD2positive without intratumor heterogeneity , tumor immunostained prior study entry Patients enter CCG3951 may become eligible following third course highdose chemotherapy follow peripheral blood stem cell ( PBSC ) rescue ; patient treat institutional ( local ) protocol highdose chemotherapy PBSC rescue may also become eligible one course PBSC rescue Patients must enter onto study within 8 week total absolute phagocyte count [ neutrophil ( segs + band ) + monocyte ] &gt; 1,000/uL ; APC criterion include count obtain GCSF therapy Patients must performance status 0 , 1 2 patient must life expectancy &gt; = 2 month Serum creatinine = &lt; 1.5 x normal , creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 60 ml/min/1.73 m^2 Total bilirubin = &lt; 1.5 x normal Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) = &lt; 5 x normal Venoocclusive disease , present , stable improve Shortening fraction &gt; = 27 % echocardiogram , ejection fraction &gt; 50 % gate radionuclide study Forced expiratory volume 1 second ( FEV1 ) force vital capacity ( FVC ) &gt; 60 % predict pulmonary function test For child unable pulmonary function test ( PFTs ) , evidence dyspnea rest , exercise intolerance , pulse oximetry &gt; 94 % room air Patients seizure disorder may enrol anticonvulsant well controlled Central nervous system ( CNS ) toxicity &lt; grade 2 Patients must double lumen catheter single lumen peripheral IV interleukin ( IL ) 2 ch14.18 give separately Patients remain evaluable response Phase II/III study ( i.e . CCG3891 ) eligible study ; however , patient treat Phase I study ( i.e . CCG3951 ) patient longer evaluable Phase II/III study ( i.e . progressive disease follow therapy ) eligible Patients previously treat antibody 14.G2a ch14.18 ineligible study Patients require chronic use corticosteroid ineligible Corticosteroid , immunosuppressive drug , myelosuppressive chemotherapy , retinoic acid must give within 14 day prior study entry Radiation therapy must give within seven day prior study entry therapy All patient and/or parent legal guardian must sign write informed consent All institutional , FDA , NCI requirement human study must meet</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>